AZD9291
AstraZeneca earns ‘speedy’ FDA approval for lung cancer drug
November 13, 2015AZD9291, AstraZeneca, Tagrisso, lung cancer
The FDA has approved AstraZeneca’s new lung cancer drug Tagrisso, in a record two and half years from development, under …
AstraZeneca halts lung cancer trials amidst safety concerns
October 13, 2015Manufacturing and Production AZD9291, AstraZeneca, MEDI4736, NSCLC, drug safety, durvalumab, interstitial lung disease, lung cancer, non-small cell lung cancer
AstraZeneca is stopping two trials of a combination of two of its pipeline cancer treatments, after reports that the pairing …
Lung cancer market to hit $10.9bn by 2021
September 10, 2015Sales and Marketing AZD9291, GBI Research, GlobalData, NSCLC, industry analysis, industry intelligence, industry reports, keytruda, market intelligence lung cancer, market reports, market trends, non small cell lung cancer, non-small cell lung cancer, opdivo, world conference on lung cancer
The global market value for non-small cell lung cancer treatment will rise from $6.9 billion in 2014 to $10.9 billion …
AstraZeneca lung cancer drug clears UK market access hurdle
September 4, 2015Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer
Follow @Pharmafocus
AstraZeneca lung drug shines on
June 1, 2015Sales and Marketing ASCO, AZD9291, AstraZeneca, MEDI4736, NSCLC, Tafinlar
AstraZeneca’s investigational drug AZD9291 is continuing to impress, with results announced at cancer conference ASCO building on its previous ‘unprecedented’ …
AstraZeneca lung drug shows promise
April 20, 2015Sales and Marketing AZ, AZD9291, AstraZeneca, European Lung Cancer Congress, NSCLC, Orphan
AstraZeneca’s non-small cell lung cancer offering AZD9291 has been shown to delay disease progression by over a year. Data presented …
AZ predicts strong growth ahead of Pfizer deadline
November 19, 2014Sales and Marketing AZD9291, AstraZeneca, Pfizer, Soriot, definiens
AstraZeneca has announced that it expects to deliver revenues of over $45 billion by 2023 as it makes its final …
Profits slump at AstraZeneca
April 24, 2014Sales and Marketing AZD9291, AstraZeneca, BMS, Brilinta, Q1
AstraZeneca has continued its poor run of form, with operating profit in the first quarter of 2014 falling 40% on …
Latest content
Five Facts about cardiovascular disease
